Perry C Siatis Sells $5.15M of AbbVie Inc (ABBV) — SEC Form 4, Feb 27, 2026
Open-Market Net Sale · SEC Form 4
−$5,147,630
10b5-1 Plan
Equity Position
60.5K sh
60,518 → 60,518
Filing Lag
2 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Perry C Siatis CIK 0001951400 |
EVP
|
Perry C Siatis at AbbVie Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
$9,523,179
More from this insider at AbbVie Inc
| 2026-03-03 | Sell | -$4,375,549 | View |
| 2026-02-20 | Award | — | View |
| 2025-03-04 | Sell | -$5,822,402 | View |
| 2025-02-24 | Sell | -$1,143,452 | View |
| 2025-02-18 | Award | — | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock, $0.01 par value | 2026-02-25 | M - Exercise 10b5-1 | 7,314 A | $149.62 | +$1,094,321 | 45,451 | Direct |
| Common Stock, $0.01 par value | 2026-02-25 | M - Exercise 10b5-1 | 7,775 A | $175.28 | +$1,362,802 | 53,226 | Direct |
| Common Stock, $0.01 par value | 2026-02-25 | M - Exercise 10b5-1 | 7,292 A | $192.86 | +$1,406,335 | 60,518 | Direct |
| Common Stock, $0.01 par value | 2026-02-25 | S - Sale 10b5-1 | 22,381 D | $230.00 | -$5,147,630 | 38,137 | Direct |
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Option (Right to buy)F1 | $149.62 | 2026-02-25 | M - Exercise 10b5-1 | 7,314 D | $149.62 | 2033-02-15 | 7,314 Common Stock | Direct |
| Option (Right to buy)F2 | $175.28 | 2026-02-25 | M - Exercise 10b5-1 | 7,775 D | $175.28 | 2034-02-14 | 7,775 Common Stock | Direct |
| Option (Right to buy)F3 | $192.86 | 2026-02-25 | M - Exercise 10b5-1 | 7,292 D | $192.86 | 2035-02-12 | 7,292 Common Stock | Direct |
Footnotes (3)
- F1
- Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 7,315 on February 16, 2024, 7,315 on February 16, 2025, and 7,314 on February 16, 2026. Show more
- F2
- Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 7,775 on February 15, 2025 and 7,775 on February 15, 2026, and becomes exercisable as to 7,774 shares on February 15, 2027. Show more
- F3
- Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 7,292 shares on February 13, 2026 and becomes exercisable in annual increments of 7,292 on February 13, 2027, and 7,291 on February 13, 2028. Show more
Related filings at AbbVie Inc
Institutional Holders
13F holders · Jun 30, 2026
4,249
institutional managers reporting a position
Largest by reported value
- Black Rock, Inc. $37.6B
- Vanguard Capital Management Llc $29B
- State Street Corporation $20.8B
5%+ Holders · 13D/G
1 filer
Other insiders at AbbVie Inc
GET /v1/forms/4/0001951400-26-000004
API docs
View Original SEC Filing